HG6 Stock Overview
A specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Mayne Pharma Group Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$2.52 |
| 52 Week High | AU$4.44 |
| 52 Week Low | AU$2.18 |
| Beta | 1.25 |
| 11 Month Change | -11.89% |
| 3 Month Change | -3.82% |
| 1 Year Change | -8.70% |
| 33 Year Change | -25.44% |
| 5 Year Change | -52.27% |
| Change since IPO | -65.95% |
Recent News & Updates
Recent updates
Shareholder Returns
| HG6 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -13.1% | -5.0% | -1.3% |
| 1Y | -8.7% | -22.0% | 7.4% |
Return vs Industry: HG6 exceeded the German Pharmaceuticals industry which returned -21.6% over the past year.
Return vs Market: HG6 underperformed the German Market which returned 7.1% over the past year.
Price Volatility
| HG6 volatility | |
|---|---|
| HG6 Average Weekly Movement | 8.3% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: HG6's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: HG6's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | n/a | Shawn O’Brien | www.maynepharma.com |
Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. The company operates through three segments: Women’s Health, Dermatology, and International. It provides oral drug delivery systems; and contract development and manufacturing services to third-party customers, as well as distributes specialty pharmaceutical products in the dermatology, women’s health, and infectious disease therapeutic areas.
Mayne Pharma Group Limited Fundamentals Summary
| HG6 fundamental statistics | |
|---|---|
| Market cap | €210.78m |
| Earnings (TTM) | -€104.78m |
| Revenue (TTM) | €241.36m |
0.9x
P/S Ratio-2.0x
P/E RatioIs HG6 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HG6 income statement (TTM) | |
|---|---|
| Revenue | AU$388.40m |
| Cost of Revenue | AU$169.62m |
| Gross Profit | AU$218.78m |
| Other Expenses | AU$387.39m |
| Earnings | -AU$168.62m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.08 |
| Gross Margin | 56.33% |
| Net Profit Margin | -43.41% |
| Debt/Equity Ratio | 7.0% |
How did HG6 perform over the long term?
See historical performance and comparison